Skip to main content
      A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension

      Antoni Chan MD (Prof) synovialjoints

      9 months 3 weeks ago
      A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension studies of JAKi and TNFi, in adults with RA, PsO, PsA, axial spondyloarthritis axSpA and IBD showed the following: - TNFi was associated with a significantly… https://t.co/FWHgemEAvG https://t.co/3D0nldwmwA
      Nipocalimab, an anti-neonatal Fc receptor (FcRn) mAb, reduces circulating IgG including specific autoantibodies (AAb), b

      Antoni Chan MD (Prof) synovialjoints

      9 months 3 weeks ago
      Nipocalimab, an anti-neonatal Fc receptor (FcRn) mAb, reduces circulating IgG including specific autoantibodies (AAb), by selectively blocking IgG–FcRn interactions. DAHLIAS, the first study of a FcRn blocker in SjD, showed that nipocalimab led to significant improvement vs PBO… https://t.co/zl1tEsEMAj https://t.co/qrkOD2Ccc3
      A#2527 DAHLIAS, P2Nipocalimab: Anti-FcRn Ab in Ro+ SjDIV 5 or 15 mg/kgPrim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4

      Eric Dein ericdeinmd

      9 months 3 weeks ago

      A#2527 DAHLIAS, P2 Nipocalimab: Anti-FcRn Ab in Ro+ SjD IV 5 or 15 mg/kg Prim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4 v -3.7 PBO p=0.002 Improv dryness, fatigue, pain Better unstim salivary flow Best response in higher Ab titer pts Safety data good #ACRBest #ACR24 @RheumNow https://t.co/O7zahPul66

      Phase 2 DAHLIA study in SjogrensAnti-neonatal Fc receptor an “nipocalimab” w/remarkably encouraging resultsclinE

      Mike Putman EBRheum

      9 months 3 weeks ago

      Phase 2 DAHLIA study in Sjogrens Anti-neonatal Fc receptor an “nipocalimab” w/remarkably encouraging results clinESSDAI significantly better at wk24, notably met QOL domains as well Finally getting good news in SjS! #ACR24 @RheumNow #ACRbest Abst#2527 https://t.co/e3uQmqJZ1o

      Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly. This may be particularly true for the TYK/JAK/STAT signaling pathway, where each agent has a slightly-different combination of binding affinity to various JAK and TYK signaling dimers. In this article I want to share some
      📢 Late breaking #2002

      ➡️In ICI-induced arthritis, patients (n=100) report worsened pain, fatigue, & physical

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 3 weeks ago
      📢 Late breaking #2002 ➡️In ICI-induced arthritis, patients (n=100) report worsened pain, fatigue, & physical function vs population norms. ➡️High disease activity worsens symptoms #acr24 @RheumNow @jhrheumatology
      If a mother has had TNFi during pregnancy, can a baby have a live oral rotavirus vaccine (usually at 2mo)?

      This claims

      David Liew drdavidliew

      9 months 3 weeks ago
      If a mother has had TNFi during pregnancy, can a baby have a live oral rotavirus vaccine (usually at 2mo)? This claims data suggests no increase in diarrhoea Adds to similarly reassuring 🇨🇦prospective cohort data https://t.co/2Tz9zRhPjz Vaccinate away! #ACR24 ABST0806 @RheumNow https://t.co/66OIAR8W6l
      We use steroids carefully during pregnancy, and with good reason.

      SLR from @eular_org Task Force shows a dose-dependent

      David Liew drdavidliew

      9 months 3 weeks ago
      We use steroids carefully during pregnancy, and with good reason. SLR from @eular_org Task Force shows a dose-dependent effect of glucocorticoids on preterm birth. (of course, stable autoimmune disease hopefully means avoiding steroids altogether) #ACR24 ABST0810 @RheumNow https://t.co/elWsx5IXtB
      📢Late-breaking #2003🔑 Cappelli et al @jhrheumatology finds hip OA is NOT a significant risk factor for #ICI-IA

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 3 weeks ago

      📢Late-breaking #2003 🔑 Cappelli et al @jhrheumatology finds hip OA is NOT a significant risk factor for #ICI-IA 🔴#ICI-IA linked to lower mortality #ACR24 #ACRBest @RheumNow

      Control RA, Build Stronger Bones
      Shifting Trends in Initial RA Treatment Approaches

      A recent study by Sparks et al (Abstract #0509) reveals evolving tre

      Dr. John Cush RheumNow

      9 months 3 weeks ago
      Shifting Trends in Initial RA Treatment Approaches A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for rheumatoid arthritis (RA) over two decades in the U.S. https://t.co/6FN0WayZZR #ACR24 https://t.co/dc3CiNpKmx
      Abst#2413 SLE Cohort of > 2900 pts over 50 yrs - Prevalence of proteinuria at the time of SLE dx has not changed over

      TheDaoIndex KDAO2011

      9 months 3 weeks ago
      Abst#2413 SLE Cohort of > 2900 pts over 50 yrs - Prevalence of proteinuria at the time of SLE dx has not changed over the decades. Prevalence of proteinuria also did not change at 5 and 10 yrs after dx. Earlier use of HCQ has not led to a ⬇️in lupus nephritis. @RheumNow #ACRbest
      Nice data from the OTIS Autoimmune Disease in Pregnancy Project re: certolizumab-exposed pregnancies:
      - spontaneous loss

      David Liew drdavidliew

      9 months 3 weeks ago
      Nice data from the OTIS Autoimmune Disease in Pregnancy Project re: certolizumab-exposed pregnancies: - spontaneous loss rate comparable to non-disease controls - no stillbirths - preterm similar to disease controls Plenty positive for CZP in pregnancy! #ACR24 ABST0805 @RheumNow https://t.co/XCRYsioxC0
      ×